These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37276270)

  • 1. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
    Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
    Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
    Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
    World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
    Arnold SM; Chansky K; Baggstrom MQ; Thompson MA; Sanborn RE; Villano JL; Waqar SN; Hamm J; Leggas M; Willis M; Rosales J; Crowley JJ
    Clin Lung Cancer; 2020 Jul; 21(4):357-364.e7. PubMed ID: 32173247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
    Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
    Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
    Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C
    J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
    Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E; Rebersek M; Hlebanja Z; Ocvirk J
    BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
    Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
    Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.
    Annic J; Babey H; Corre R; Descourt R; Quéré G; Renaud E; Lambert M; Le Noac'h P; Dhamelincourt E; Nguyen J; Vu A; Bourbonne V; Robinet G; Geier M
    Cancer Med; 2023 Feb; 12(3):2658-2665. PubMed ID: 36000584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
    Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
    Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
    Paz-Ares L; Spigel DR; Chen Y; Jove M; Juan-Vidal O; Rich P; Hayes T; Calderón VG; Caro RB; Navarro A; Dowlati A; Zhang B; Moore Y; Yao X; Kokhreidze J; Ponce S; Bunn PA
    Cancer; 2022 May; 128(9):1801-1811. PubMed ID: 35195913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
    Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
    J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
    Kondo R; Watanabe S; Shoji S; Ichikawa K; Abe T; Baba J; Tanaka J; Tsukada H; Terada M; Sato K; Maruyama Y; Makino M; Hirata A; Tanaka H; Koya T; Yoshizawa H; Kikuchi T
    Oncology; 2018; 94(4):223-232. PubMed ID: 29444512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
    Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
    JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.